Fig. 2: Sphingosine 18:1 aggravates NASH.
From: Sphingosine d18:1 promotes nonalcoholic steatohepatitis by inhibiting macrophage HIF-2α
CDAA-HFD-fed mice were treated with vehicle, sphingosine 16:1 or sphingosine 18:1 for 8 weeks (n = 6 mice/group). A Liver weights. B Ratios of liver mass to body mass. C Serum ALT. D Serum AST. E Representative H&E (up), and Sirius Red (down) staining of liver sections. The circles marked the inflammation foci. n = 3 mice per group, 3 images per mouse. Scale bar is 100 μm. F The percentage of fibrosis area. G–J Histology scores of hepatic steatosis (G), lobular inflammation (H), ballooning (I), and NAFLD activity (J). K, L Relative mRNA levels of genes related to hepatic inflammation (K) and fibrosis (L). n = 6 biologically independent samples. Data are the means ± s.e.m. A, C, D, F, K, L Statistical analysis was performed using One-way ANOVA; B, G–J Col5a2 in L, statistical analysis was performed using Kruskal–Wallis test with Dunn’s test.
